Congressman Calls on Colleagues to Urge DEA to Permit Psilocybin Access

Rep. Earl Blumenauer is asking fellow legislators to join him in urging the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted. In a letter circulated by Blumenauer, he notes that there are federal as well as state right-to-try legislations that should allow particular patients to access the psychedelic as an investigational treatment.

Blumenauer states in the letter that there existed a growing body of evidence pointing to the effectiveness and safety of psilocybin-assisted therapy as a possible way to provide care to people with anxiety and/or treatment-resistant depression. He further explains that despite these promising findings, the pace of regulatory approval had been slow for a substance that occurred naturally, which had evidence of its safe therapeutic use by humans for millennia. The congressman is urging his colleagues to sign on to a letter that’s been addressed to Anne Milgram, the current administrator of the DEA.

Thus far, 41 states as well as Congress have adopted right-to-try laws, which permit patients with terminal illnesses to try investigational drugs that are yet to receive approval for general use. Despite the potential therapeutic benefits of psilocybin as evidenced by various clinical trials, the DEA continues to deny access to the substance.

This restriction of access has already resulted in the filing of a lawsuit by a doctor in Washington State who requested federal approval to treat his terminally ill patients with magic mushrooms and was informed that there wasn’t a legal route for him to do so. The lawsuit against the Drug Enforcement Administration (“DEA”) was filed by Dr. Sunil Aggarwal of the Advanced Integrative Medical Science (“AIMS”) Institute, an oncology clinic. It has been brought before the U.S. Court of Appeal for the 9th Circuit.

In his statement, Aggarwal stated that high-quality clinical evidence had demonstrated that psilocybin-assisted therapy could help give rise to joy, connection and awe, which could influence demoralization, mood, immune function and possibly even prognosis in terminally ill patients.

The attorney general’s office in Washington State has joined the plaintiffs, voicing its support for the right to access to psilocybin. The court heard oral arguments of the case in September. However, a ruling hasn’t been made yet.

In a separate interview, Blumenauer stated that he was excited about the implementation of a psilocybin therapy program being established in Oregon, his home state, as well as the advancements being made in psychedelic research. Many companies, including Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), are also offering ketamine infusions in jurisdictions where such treatments are legal, and many patients are benefiting from the remedies.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.